Schedule 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

 

BioLineRx, Ltd.

(Name of Issuer)

 

 

American Depositary Receipts

(Title of Class of Securities)

09071M106

(CUSIP Number)

December 31, 2011

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 09071M106  

 

  1   

Names of Reporting Persons

 

Teva Pharmaceutical Industries Limited

  2  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ¨        (b)  x

 

  3  

SEC Use Only

 

  4  

Citizenship or Place of Organization

 

    Israel

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

    5    

Sole Voting Power

 

    1,188,953 American Depositary Receipts

   6   

Shared Voting Power

 

    0 shares of common stock

   7   

Sole Dispositive Power

 

    1,188,953 American Depositary Receipts

   8   

Shared Dispositive Power

 

    0 shares of common stock

  9

  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

    1,188,953 American Depositary Receipts

10

  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

 

11

  

Percent of Class Represented by Amount in Row (9)

 

    9.6%

12

  

Type of Reporting Person (See Instructions)

 

    CO

 

Item 1  

(a)

    Name of Issuer:      
     BioLineRx Ltd.      
Item 1  

(b)

    Address of Issuer’s Principal Executive Offices:      
     PO Box 45158, 19 Hartum Street, Jerusalem L3 91450      
Item 2  

(a)

    Name of Person Filing:      
     Teva Pharmaceutical Industries Limited      
         2  

(b)

    Address or Principal Business Office or, if none, Residence:      
     5 Basel Street, P.O. Box 3190 Petach Tikva 49131 Israel      
         2  

(c)

    Citizenship:      
     Israel      
         2  

(d)

    Title of Class of Securities:      
     American Depositary Receipts      
         2  

(e)

    CUSIP No.:      
     09071M106      
Item 3.   If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: N/A   
  (a)    ¨    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
  (b)    ¨    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c)    ¨    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d)    ¨    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
  (e)    ¨    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
  (f)    ¨    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
  (g)    ¨    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
  (h)    ¨    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i)    ¨    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  (j)    ¨    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
  (k)    ¨    Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with
        § 240.13d–1(b)(1)(ii)(J), please specify the type of institution :                    

Item 4.    Ownership -      
   Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.      
   (a)    Amount beneficially owned:      
      1,188,953 American Depositary Receipts1      
   (b)    Percent of class:      
      9.6%.      
   (c)    Number of shares as to which the person has:      
      (i)    Sole power to vote or to direct the vote      
         1,188,953 American Depositary Receipts      
      (ii)    Shared power to vote or to direct the vote      
         0 shares of common stock      
      (iii)    Sole power to dispose or to direct the disposition of      
         1,188,953 American Depositary Receipts      
      (iv)    Shared power to dispose or to direct the disposition of      
         0 shares of common stock.      
   Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d–3(d)(1).      
Item 5.    Ownership of 5 Percent or Less of a Class. N/A   
   If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ¨.   
   Instruction. Dissolution of a group requires a response to this item.   
Item 6.    N/A      
   Ownership of More than 5 Percent on Behalf of Another Person. If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.      
Item 7.    N/A
   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. If a parent holding company or control person has filed this schedule pursuant to Rule 13d—1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d—1(c) or Rule 13d—1(d), attach an exhibit stating the identification of the relevant subsidiary.
Item 8.    N/A      
   Identification and Classification of Members of the Group      
   If a group has filed this schedule pursuant to §240.13d—1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d—1(c) or Rule 13d—1(d), attach an exhibit stating the identity of each member of the group.      
Item 9.    N/A      
   Notice of Dissolution of Group. Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.      
Item 10.    Certifications      
   The following certification shall be included if the statement is filed pursuant to §240.13d—1(c):      
   By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.      

 

1 

Teva beneficially holds 1,188,953 American Depositary Receipts, which represents 11,889,535 underlying ordinary shares. BioLine has listed American Depositary Receipts (“ADRs”) for trading on NASDAQ, each ADR representing 10 ordinary shares.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 14, 2012     By:
   

/s/ Eyal Desheh

    Name: Eyal Desheh
    Title: Chief Financial Officer

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, Provided, however, That a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d—7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).